Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Accumulated Expenses (2021 - 2026)

Centessa Pharmaceuticals has reported Accumulated Expenses over the past 5 years, most recently at $35.4 million for Q4 2025.

  • Quarterly Accumulated Expenses fell 30.48% to $35.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.4 million through Dec 2025, down 30.48% year-over-year, with the annual reading at $35.4 million for FY2025, 30.48% down from the prior year.
  • Accumulated Expenses was $35.4 million for Q4 2025 at Centessa Pharmaceuticals, up from $20.4 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $50.9 million in Q4 2024 and troughed at $15.3 million in Q1 2023.
  • The 5-year median for Accumulated Expenses is $22.8 million (2023), against an average of $24.4 million.
  • Year-over-year, Accumulated Expenses surged 84.46% in 2024 and then tumbled 30.48% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $16.6 million in 2021, then soared by 47.84% to $24.5 million in 2022, then increased by 12.52% to $27.6 million in 2023, then surged by 84.46% to $50.9 million in 2024, then tumbled by 30.48% to $35.4 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Accumulated Expenses are $35.4 million (Q4 2025), $20.4 million (Q3 2025), and $24.0 million (Q2 2025).